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PLINICAL RESEARCH Clinical Trial
Randomized, Double-Blind,
lacebo-Controlled Trial on Restenosis Prevention
y the Receptor Tyrosine Kinase Inhibitor Imatinib
ietlind Zohlnhöfer, MD,* Jörg Hausleiter, MD,* Adnan Kastrati, MD,* Julinda Mehilli, MD,*
hristoph Goos,* Helmut Schühlen, MD,* Jürgen Pache, MD,* Gisela Pogatsa-Murray, MD,*
we Heemann, MD,† Josef Dirschinger, MD,‡ Albert Schömig, MD*
unich, Germany
OBJECTIVES The aim of the present double-blind, placebo-controlled study was to evaluate the efficacy of
a systemic imatinib treatment, a potent platelet-derived growth factor (PDGF) receptor
kinase inhibitor, for the prevention of recurrent restenosis in patients with in-stent restenosis
(ISR).
BACKGROUND Neointima proliferation after stent placement has been associated with the effect of potent
mitogenes such as PDGF, and their inhibition has resulted in reduction of neointima
formation in experimental models.
METHODS A total of 180 patients with either symptoms or a positive stress test in the presence of
angiographically signficiant ISR were randomly assigned to two treatment arms: imatinib
treatment or placebo. Patients received imatinib (600 mg/day) for 10 days starting 2 days
before repeat intervention. Angiographic restenosis at follow-up angiography was the primary
end point of the study.
RESULTS Repeat angiography was performed in 160 of 180 patients (88.9%). The combined rate of
death or MI at one year was 1.0% in patients randomized to either group (p  0.67).
Compared with the placebo group, imatinib treatment did not affect the angiographic
restenosis rate (38.8% with imatinib vs. 41.3% with placebo; p  0.75). Similarily, the need
for target lesion revascularization did not differ between both groups (28.1% with imatinib vs.
28.6% with placebo; p  0.94).
CONCLUSIONS Systemic imatinib therapy does not affect the risk of recurrence in patients with
ISR. (J Am Coll Cardiol 2005;46:1999 –2003) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.07.060Cardiology Foundation
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pn-stent restenosis (ISR) after successful coronary stent
lacement is still a challenging clinical problem. Plain balloon
ngioplasty, cutting balloon angioplasty, and rotational
therectomy for ISR are associated with a high recurrence rate
1–3). The use of intracoronary brachytherapy resulted in
ignificant reduction of restenosis at 6 to 12 months, but an
ncreased rate of late recurrences in the irradiated arteries
as raised the question about the durability of the early
enefit in the long term (4). In contrast, the placement of
rug-eluting stents (5) and the systemic treatment with
apamycin (6) have resulted in significant reductions of the
isk of restenosis recurrence. The predominant mechanism
f ISR is neointimal tissue proliferation (7), and the cellular
omponent of the neointima is mainly comprised of smooth
uscle cells (8), attracted from the media through inflam-
atory chemokines and mitogenes (9). The platelet-derived
rowth factor (PDGF) was shown to play a pivotal role in
From the *Deutsches Herzzentrum München, Munich, Germany; Klinik an der
echnische Universität München, Munich, Germany; †2.Medizinische Klinik des
linikum rechts der Isar, Technische Universität, Munich, Germany; and ‡1.Medi-
inische Klinik des Klinikums rechts der Isar, Technische Universität, Munich,
ermany. The first two authors contributed equally to this work.t
Manuscript received May 10, 2005; revised manuscript received July 13, 2005,
ccepted July 18, 2005.he proliferative and migratory response of smooth muscle
ells (SMCs) to vascular injury (10), and inhibition of
DGF by blocking antibodies significantly reduced neoin-
ima formation in a mouse model of restenosis (11).
urthermore, it has been shown that c-Kit progenitor cells
re able to differentiate into -actin positive SMCs in vitro
nd in vivo and may contribute to neointima formation after
ascular injury (12). The proliferation and differentiation of
-Kit progenitor cells is regulated by the c-Kit receptor
inase and its ligand, stem cell factor (13).
Imatinib, a potent inhibitor of receptor tyrosine kinases,
s known to inhibit simultaneously the PDGF receptor kinase,
he bcr-abl tyrosine kinase as well as the c-Kit receptor kinase
14). It has been approved for the treatment of patients with
hiladelphia (bcr-abl) chromosome-positive chronic my-
loid leukemia (CML) and of patients with c-Kit (CD
17)-positive gastrointestinal stromal tumors (GISTs). Fur-
hermore, imatinib was able to prevent restenosis after
epeated vascular injury in a mouse model of restenosis (15).
he simultaneous inhibition of the PDGF receptor as well
s of the c-KIT receptor kinase by imatinib provides a
ationale for its use in the prevention of restenosis after
ercutaneous coronary intervention. Therefore, the objec-
ive of this randomized, placebo-controlled, double-blind
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Oral Imatinib for ISR December 6, 2005:1999–2003rial was to assess whether an oral administration of ima-
inib, including a pretreatment for two days, is associated
ith a reduction of restenosis after percutaneous coronary
ntervention (PCI) in patients with ISR.
ETHODS
atients. Eligible patients had angina pectoris and/or a
ositive stress test and presented with angiographically
ignificant ISR (lumen renarrowing of50% at a previously
tented segment) in native coronary vessels. Patients with
cute coronary syndromes, presence of severe kidney failure
serum creatinine 2.2 mg/dl), or contraindications to the
edication used in the present study were excluded. The
tudy was conducted according to the principles of the Dec-
aration of Helsinki and approved by the institutional ethics
ommittees. All patients had given their written informed
onsent for participation in this trial.
andomization, medication, and coronary procedures.
fter diagnosing the presence of significant ISR by coronary
ngiography, patients were randomly assigned to oral ima-
inib (Glivec, Novartis International AG, Basel Switzer-
and) with 600 mg/day or placebo. Randomization was
erformed in a double-blind manner with the use of sealed
nvelopes containing the block randomization sequence for
ach participating center. Double blinding was achieved by
he use of similar-appearing capsules containing imatinib or
lacebo. A pretreatment with imatinib/placebo was started
days before repeat PCI, which was performed on day 3.
fter the PCI, the oral treatment was continued for
dditional 7 days (day 4 to 10 after PCI).
The protocol of repeat intervention for ISR has been
escribed elsewhere (1). In brief, all patients received clopi-
ogrel 600 mg at least 2 h before and 500 mg intravenous
spirin immediately before the intervention. Conventional
ngioplasty balloon catheters were used for repeat dilation to
chieve a final diameter stenosis of30% and Thrombolysis
n Myocardial Infarction flow grade 3 at the end of
rocedure. Additional stents were placed in the presence of
suboptimal result or a large residual dissection (5 mm in
ength) after angioplasty. The after-procedural antithrom-
otic regimen consisted of 75 mg of clopidogrel for at least
months after repeat intervention; 100 mg of aspirin twice
Abbreviations and Acronyms
CI  confidence interval
CML  chronic myeloid leukemia
GIST  gastrointestinal stromal tumor
ISR  in-stent restenosis
MI  myocardial infarction
MLD  minimum lumen diameter
PCI  percutaneous coronary intervention
PDGF platelet-derived growth factor
SMC  smooth muscle cell
TLR  target lesion revascularizationaily was administered continuously. Blood cell counts and tiver and kidney function were assessed before and at the
nd of the treatment.
ngiographic evaluation. Qualitative and quantitative as-
essments in the core angiographic laboratory were per-
ormed before unblinding of the study. In-stent restenotic
esions were categorized with the classification system pro-
osed by Mehran et al. (16). Digital angiograms were
nalyzed offline with the automated edge detection system
CMS, Medis Medical Imaging Systems, Nuenen, the
etherlands). The analysis segment comprised the segment
njured by balloon angioplasty and the proximal and distal
dges, defined as 5 mm proximal or distal to the balloon-
njured segment. Matched views were selected for angio-
rams recorded before and immediately after the interven-
ion and at follow-up. Angiographic sequences were preceded
y an intracoronary injection of nitroglycerin. The param-
ters obtained were minimum lumen diameter (MLD),
essel size, diameter stenosis, and diameter of the maximally
nflated balloon. Late lumen loss was calculated as the
ifference in MLD measured between measurements after
he procedure and at follow-up. Net gain was defined as the
ifference between MLD at follow-up and before balloon
ilation.
efinitions and end points of the study. Angiographic
estenosis at follow-up, defined as diameter stenosis 50%,
as the primary end point. Secondary end points were the
ombined incidence of death or myocardial infarction (MI),
s well as target lesion revascularization (TLR), PCI, or
ypass surgery during one-year follow-up. The diagnosis of
I was based on typical chest pain combined with either
ew pathologic Q waves or creatinine kinase rise 3 times
he upper limit of normal with concomitant increase in the
B isoenzyme. Creatine kinase was determined before and
mmediately after the procedure, every 8 h for the first 24 h
fter the procedure, and daily afterward until discharge.
arget lesion revascularization was performed in the pres-
nce of angiographic restenosis and symptoms or signs of
schemia. Adverse events were monitored throughout the
ollow-up period by a clinical visit at six months and an
dditional telephone interview at one year after the inter-
ention. If patients reported cardiac symptoms during the
elephone interview, at least a clinical and electrocardio-
raphic follow-up examination were performed in the out-
atient clinic or by the referring physician. All events were
djudicated and classified by an event-adjudication commit-
ee whose members were unaware of the patients’ assigned
reatment.
tatistical analysis. The sample size estimation was based
n the following assumptions: a two-sided alpha-level of
.05 and power of 80% and an angiographic restenosis rate
f 40% in the placebo group and 20% in the imatinib group.
ccordingly, a sample size of 70 patients in each group was
alculated; we enrolled a total of 180 patients to accommo-
ate for missing angiographic follow-up studies.
The main analysis was performed on an intention-to-reat basis and the discrete variables are expressed as counts
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December 6, 2005:1999–2003 Oral Imatinib for ISRr percentages and compared with chi-square or Fisher
xact test (whenever an expected cell value was 5); for the
utcome variables, the relative risk and its 95% confidence
nterval (CI) were computed for outcome measures. Con-
inuous variables are expressed as mean SD and compared
y means of the unpaired two-sided t test. Statistical signifi-
ance was accepted for p  0.05.
ESULTS
etween December 2002 and June 2003, a total of 180
onsecutive patients were randomized to receive imatinib
n  89) or placebo (n  91). Baseline clinical, angiographic,
nd procedural characteristics are shown in Table 1. A
iffuse ISR morphology was less prevalent in the imatinib
roup; all other characteristics were comparable between
oth groups.
arly clinical follow-up. Twenty patients (22.5%) treated
ith oral imatinib experienced potential drug-related side
ffects. The majority of these patients complained about
ild to moderate gastrointestinal complaints, including
able 1. Baseline Clinical, Angiographic, and
rocedural Characteristics
Placebo
(n  91)
Imatinib
(n  89)
p
Value
linical characteristics
Age, yrs 66.1  10.2 66.4  9.8 0.85
Women, % 22.0 19.1 0.63
Diabetes, % 29.7 22.5 0.27
Current smokers, % 12.1 12.4 0.96
Hypercholesterolemia, % 61.5 66.3 0.51
Arterial hypertension, % 67.0 57.3 0.18
Previous myocardial
infarction, %
39.6 51.7 0.10
Previous bypass surgery, % 11.0 10.1 0.85
ngiographic characteristics
Left ventricular ejection
fraction, %
55.0  11.4 55.8  12.5 0.67
Target vessel 0.16
LCA, % 1.1 2.3
LAD, % 56.0 39.3
LCx, % 19.8 28.1
RCA, % 23.1 30.3
Diffuse restenosis
morphology, %*
52.7 37.1 0.03
Vessel size, mm 2.60  0.46 2.56  0.51 0.54
Diameter stenosis, % 66.0  13.5 63.6  13.7 0.24
Lesion length, mm 15.6  7.7 13.7  7.2 0.08
rocedural data
Maximal balloon pressure,
atm
13.0  3.0 12.8  3.3 0.72
Balloon-to-vessel ratio 1.15  0.17 1.13  0.21 0.62
Repeat intervention 0.44
Balloon angioplasty, % 90.1 93.3
New stent placement, % 9.9 6.7
Minimum lumen diameter
after procedure, mm
2.12  0.45 2.08  0.47 0.51
Final diameter stenosis, % 21.0  8.7 21.8  11.8 0.62
ISR morphology was assessed on the basis of the classification system by Mehran
t al. (16).LAD left anterior descending coronary artery; LCA left main coronary artery;
Cx  left circumflex coronary artery; RCA  right coronary artery.
r
Wausea, vomiting, and diarrhea; the medication needed to be
iscontinued in four (4.5%) patients owing to extensive
iarrhea. Additional side effects included pruritus and ex-
nthema. At the end of the treatment duration, no hema-
ologic adverse effects were observed. Furthermore, bilirubin
evels did not differ between both treatment groups. In
ontrast, a significant increase in serum creatinine was found
n the imatinib group. Although the creatinine values did
ot differ before the treatment, with 1.28  0.36 mg/dl
ersus 1.25  0.46 mg/dl (p  0.72), the creatinine values
ncreased at the end of the 10-day treatment to 1.56  0.37
g/dl versus 1.29  0.40 mg/dl (p  0.001) for imatinib
ersus placebo, respectively.
None of the patients had a thrombotic vessel occlusion or
ied within the 30 days after PCI. One patient in each
roup developed a non-fatal MI (1.1% in each treatment
roup; p  0.67).
ngiographic and late clinical follow-up. Repeat angiog-
aphy was performed in 160 of 180 patients (88.9%) at a
edian time interval of 198 days (interquartile range: 182
nd 219 days). The angiographic results are summarized in
able 2. The primary end point of the trial, angiographic
estenosis, was reached in 38.8% of imatinib patients and
1.3% of the placebo patients (relative risk 0.94; 95% CI
.62 to 1.41; p  0.75). Figure 1 illustrates the restenosis
ates in each group. Consequently, the MLD, the diameter
tenosis at follow-up, and the late lumen loss and the net
umen gain did not differ between both groups. Cumulative
istribution curves for the degree of percent diameter
tenosis at follow-up are demonstrated in Figure 2.
able 2. Angiographic Results at Follow-Up
Placebo
(n  80)
Imatinib
(n  80) p Value
inimum lumen
diameter, mm
1.54  0.61 1.48  0.63 0.49
iameter stenosis, % 43.0  21.5 44.0  18.6 0.75
ate lumen loss, mm 0.60  0.53 0.59  0.56 0.92
et lumen gain, mm 0.67  0.52 0.54  0.62 0.15
ncidence of restenosis, %
(confidence interval)
41.3 (30.5–52.0) 38.8 (28.1–49.4) 0.75
igure 1. Bar graph demonstrating angiographic restenosis rates at six
onths and clinical restenosis rates at one year (need for target lesionevascularization [TLR], repeat coronary intervention, or bypass surgery).
hite bars  placebo; black bars  imatinib.
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Oral Imatinib for ISR December 6, 2005:1999–2003At one-year clinical follow-up the combined incidence of
eath or MI was 1.1% in both groups (p  0.67). The need
or target lesion revascularization at 1 year was 28.1% in the
matinib group and 28.6% in the placebo group (relative risk
.98; 95% CI 0.59 to 1.63; p  0.94). Accordingly, the
umulative rate of major adverse cardiac events was 29.2%
nd 29.7% in the imatinib and placebo groups, respectively
p  0.75). Table 3 summarizes the clinical outcome at one
ear.
ISCUSSION
matinib is a tyrosine kinase inhibitor that inhibits three
ifferent tyrosine kinases. In patients with CML, imatinib
locks the constitutive activated bcr-abl tyrosine kinase
reated by the Philadelphia chromosome abnormality, re-
ulting in an inhibition of proliferation and induction of
poptosis in Bcr-Abl positive cell lines. The expected effect
f imatinib on restenosis prevention after PCI was based on
ts ability to simultaneously inhibit two further tyrosine
inases: the PDGF receptor and the c-Kit receptor tyrosine
inase (17). In experimental studies, PDGF was shown to
lay a pivotal role in the proliferative and migratory re-
ponse of SMCs to vascular injury, leading to neointima
ormation (10,18). The blocking of the PDGF-associated
ignal transduction pathway by antibodies against PDGF or
y tyrosine kinase inhibitors significantly reduced neointima
ormation in various restenosis models (11,15,19). Further-
ore, recruitment and differentiation of c-Kit hematopoi-
Figure 2. Percent diameter stenosis in treatment groups.
Table 3. Clinical Outcome at One Year
Placebo
(n  91)
Death, % 0
Myocardial infarction, % 1.1
Target vessel revascularization, % 28.6
Repeat PTCA, % 28.6
Bypass surgery, % 0
Cumulative event rate, % 29.7*As assessed with Fisher exact test.
CI  confidence interval; PTCA  percutaneous transluminaltic progenitor cells may play an important role in neointima
ormation after vascular injury (12). Additionally, treatment
f circulating progenitor cells with stem cell factor, the
igand of the c-Kit receptor kinase, leads to an increase in
heir adhesiveness (20,21). Therefore, the systemic inhibi-
ion of the c-Kit receptor kinase by imatinib may reduce the
dhesiveness of hematopoietic progenitor cells as well as
heir proliferation and differentiation into -actin–positive
MCs.
In the current randomized, double-blind, and placebo-
ontrolled trial, the impact of a systemic administration of
matinib was investigated in the prevention of restenosis
fter PCI in patients at high risk for recurrence. All factors
ssociated with systemic imatinib administration were ad-
ressed to account for an optimal treatment effect. The dose
f 600 mg imatinib was chosen because of its proven effects
n the treatment of patients with CML, blast crisis, or with
IST (22,23). Furthermore, we initiated imatinib treat-
ent two days before repeat intervention to allow for an
ffective drug concentration at the time of intervention.
inally, imatinib was administered for a total of 10 days, a
eriod that has been demonstrated to be effective with
ystemic rapamycin administration for restenosis prevention
n a comparable patient cohort (6). The trial demonstrates
hat imatinib did not affect angiographic and clinical pa-
ameters of recurrent restenosis after treatment of ISR.
oreover, the relatively high number of observed adverse
ffects in combination with the significant nephropathic
ffects makes imatinib an unsuitable drug candidate given
ystemically for restenosis prevention. Although a positive
ffect of imatinib used locally cannot be ruled out, the results
f this study do not encourage this approach.
The negative finding of the current study could be
xplained by two potential reasons: First, the role of PDGF
nd of the recruitment of c-Kit progenitors for the develop-
ent of restenosis after coronary intervention might be
verestimated. Second, the systematic inhibition of c-kit
nd the PDGF receptor tyrosine kinase by imatinib may not
e sufficient to antagonize the local effects of these cytokines
t the site of vascular injury. Further studies in animal
odels may help to understand the effect of imatinib on the
olecular mechanisms of neointima formation.
tudy limitations. We tested only one dose of imatinib in
his study. Although the dose of 400 to 600 mg imatinib
Imatinib
(n  89)
Relative Risk
(CI) p Value
0 Not estimable
1.1 1.02 (0.01–79.4) 0.67*
28.1 0.98 (0.62–1.56) 0.94
25.8
3.4
29.2 0.98 (0.63–1.55) 0.95coronary angioplasty.
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December 6, 2005:1999–2003 Oral Imatinib for ISRaily is effective for treating patients with CML and GISTs
24), the effective dose for treating patients with ISR is
nknown. Therefore, we cannot rule out that a higher dose
f the drug may show an inhibitory effect on restenosis.
owever, increasing doses of imatinib were associated with
higher incidence of adverse effects, resulting in a higher
ate of discontinuation of imatinib therapy (22). Although
he rate of 22.5% drug-related adverse effects seems high
ompared with the treatment-related effects in similar
tudies, such as the Oral Sirolimus to Inhibit Recurrent
n-stent Stenosis (OSIRIS) study (6), the toxicity of ima-
inib in this trial was generally lower compared with that
bserved in previous studies at comparable doses (23,24).
his might be due to the relative short imatinib treatment
f 10 days compared with the sustained treatment over
onths and years in cancer patients.
Furthermore, we tested only one duration of imatinib
reatment. Although this duration was effective in reducing
ecurrence of ISR in the OSIRIS trial (6), we cannot rule
ut that longer treatment duration could have beneficial
ffects.
onclusions. The systemic administration of the tyrosine
inase inhibitor imatinib, including a pretreatment for two
ays, did not inhibit restenosis formation after repeat
oronary intervention in patient with ISR.
eprint requests and correspondence: Dr. Dietlind Zohlnhöfer,
eutsches Herzzentrum, Lazarettstrasse 36, 80636 München,
ermany. E-mail: zohlnhoefer@dhm.mhn.de.
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